Request Demo
Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
Recent blog posts
Latest Hotspot
8 min read
NCT07718854 Sacituzumab tirumotecan Recurrent Ovarian Clear Cell Adenocarcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07718854 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07721025 LX-2006 Friedreich Ataxia Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07721025 clinical trial report covering LX-2006, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07721103 Tislelizumab Locally Advanced Esophageal Squamous Cell Carcinoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07721103 clinical trial report covering Tislelizumab, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07719556 Venetoclax Mantle-Cell Lymphoma Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07719556 clinical trial report covering Venetoclax, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720375 Galvokimig Non-cystic fibrosis bronchiectasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720375 clinical trial report covering Galvokimig, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07719530 SHR-1139 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07719530 clinical trial report covering SHR-1139, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720167 Albumin-Bound Paclitaxel Non-small cell lung cancer stage I Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720167 clinical trial report covering Albumin-Bound Paclitaxel, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720180 Fludarabine Phosphate Recurrent ovarian cancer Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720180 clinical trial report covering Fludarabine Phosphate, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
ChiCTR2600128658 SHR-1139 Plaque psoriasis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
ChiCTR2600128658 clinical trial report covering SHR-1139, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07720258 Sacituzumab tirumotecan Adenocarcinoma of small intestine Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07720258 clinical trial report covering Sacituzumab tirumotecan, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
NCT07723924 Plecanatide Constipation - functional Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
NCT07723924 clinical trial report covering Plecanatide, Phase 2, endpoints, sponsor, geography, readout timing and development white space.
Latest Hotspot
8 min read
JPRN-jRCT2021260026 Isavuconazonium Sulfate Deep mycosis Clinical Landscape Report 2026: Design, Endpoints, Sponsor and Readout Outlook
3 August 2026
JPRN-jRCT2021260026 clinical trial report covering Isavuconazonium Sulfate, Phase 2, endpoints, sponsor, geography, readout timing and development white sp